DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Biomarkers in Oncology | Access & Reimbursement | US | Malignant Melanoma, Colorectal Cancer, Ovarian Cancer | US
Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malignant…
Chimeric Antigen Receptor (CAR) T-Cell Therapy | Access & Reimbursement | US | TBD | US | 2020
The approval two CAR T-cell therapies for relapsed / refractory B-cell hematological malignancies—Novatis’ Kymriah for acute lymphoblastic leukemia (ALL) and large B-cell lymphoma and Kite…